CD20 and BCR Antibodies Induce Similar Gene Expression Changes in Lymphoma Cells
Author Information
Author(s): Franke Andreas, Niederfellner Gerhard J., Klein Christian, Burtscher Helmut
Primary Institution: Roche Diagnostics GmbH
Hypothesis
Do anti-CD20 antibodies trigger similar transcriptional responses as B cell receptor (BCR) activation in lymphoma cell lines?
Conclusion
The study suggests that anti-CD20 antibodies can trigger a BCR activation-like response in certain lymphoma cell lines.
Supporting Evidence
- Both anti-CD20 and anti-BCR antibodies induced similar gene expression changes in lymphoma cell lines.
- Specific transcription changes were observed in two out of four cell lines after anti-CD20 treatment.
- CCL3 and CCL4 secretion was significantly reduced when Syk was inhibited or silenced.
Takeaway
Researchers found that two types of antibodies can make lymphoma cells behave similarly to how they would if they were activated by their natural receptors.
Methodology
The study used antibodies against CD20 and BCR to stimulate lymphoma cell lines and analyzed gene expression changes.
Potential Biases
Potential bias due to all authors being employees of Roche, the manufacturer of rituximab.
Limitations
The study only included four lymphoma cell lines, which may limit the generalizability of the findings.
Participant Demographics
The study involved four human lymphoma cell lines: OciLy18, Z138, REC1, and SUDHL4.
Statistical Information
P-Value
6.8*10−7
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website